Comment

  • 6 March 2017

    Tapinarof poised to fill a void in psoriasis treatment

    On March 4, 2016, GSK presented late-breaking research on tapinarof, a topical non-steroidal, anti-inflammatory drug (NSAID), in patients with psoriasis at the 75th Annual American Academy of Dermatology (AAD) meeting.

  • 6 March 2017

    A new age of drug development in atopic dermatitis

    On March 4, 2016, late-breaking research on Regeneron/Sanofi’s Dupixent (dupilumab) in patients with moderate-to-severe atopic dermatitis (AD) was presented at the 75th Annual American Academy of Dermatology (AAD) meeting.

  • 28 February 2017

    PARP inhibitor market in ovarian cancer set for a showdown

    AstraZeneca’s poly(ADP-ribose) polymerase (PARP) inhibitor, Lynparza (olaparib), had enjoyed two years alone on the ovarian cancer market without direct competition until Clovis Oncology’s Rubraca (rucaparib) joined the party two months...

  • 27 February 2017

    Minoryx’s MIN-102 secures orphan drug designation

    On February 22, 2017, Minoryx Therapeutics’ lead pipeline asset, MIN-102, received Orphan Drug Designation from the FDA, following the decision by the European Medicines Agency (EMA) to award the same...